NVST Stock Forecast & Price Target

Envista Holdings is well positioned for above-market growth because its core implant franchise is reaccelerating, with the S-Series implant running ahead of plan at 18% of Nobel implants sold in 2Q across North America and Europe and expected to become the predominantly sold Nobel implant going forward. Its Spark aligner business also offers a compelling margin lever, as cost per aligner has fallen 40% over the past three years, while automation, scale benefits, and production optimization create a clear path to further earnings leverage. Management’s raised medium-term targets for core revenue growth to 2-5%, adjusted EBITDA growth to 5-8%, and adjusted EPS growth to 7-11%, alongside 100% free cash flow conversion and just 0.7x leverage, support a constructive fundamental outlook.

Envista Holdings is facing a negative setup because China orthodontic sales are being hit by VBP-related channel de-stocking, with about $10M of revenue shifted out of 3Q and an estimated $30M-$45M of revenue risk to 2027 if procedure pricing does not improve. The concern is amplified by the possibility of a similar hit to profitability and $0.10-$0.20 of EPS risk, while rising interest expense could pressure earnings further if the company refinances its $1.4B debt stack in mid-27 at a 200bp higher rate. Even though management has shown about $100M of pricing realization over the past three years, the analyst doubts that pricing power is durable in a competitive dental market, leaving upside limited by weaker volume support and potential margin compression.